CervoMed Inc. (NASDAQ:CRVO – Get Free Report) has been assigned an average recommendation of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports.
Hosted on MSN9mon
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024CervoMed (NASDAQ:CRVO) just reported results for the first quarter of 2024. CervoMed reported earnings per share of -41 cents. This was below the analyst estimate for EPS of -39 cents. The company ...
HK inno.N will handle domestic marketing and sales of the targeted cancer drug "Avastin" from global pharmaceutical company Roche for colorectal and gynecological cancers. HK inno.N noted on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback